Stemtech Corp faces acute financial stress as its latest quarterly filing exposes a dangerously low current ratio and defaults on financing agreements. Despite generating nearly $4.9 million in revenue in 2023, the company continues to incur sizable net losses, underpinned by limited disclosure of its product portfolio and sector affiliation. Structural challenges common to small health-related firms, coupled with unresolved legal disputes involving former management, constrain its ability to achieve sustainable growth or build competitive advantages.